Received 2024-12-18

Revised 2025-06-07

Accepted 2025-07-18

GMJ Copyright© 2025, Galen Medical Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/) Email:gmj@salviapub.com

 Correspondence to: Mansour Salesi, Isfahan University of Medical Science, Isfahan, Iran. Telephone Number:+989131210325 Email Address: mansour1380@yahoo.com

GMJ.2025;14:e3752

www.salviapub.com

Molahoseini M, et al.

Prevalence of Interstitial Lung Disease in Patients with Primary Sjogren’s Syndrome

2	GMJ.2025;14:e3752 www.gmj.ir

Introduction

Primary Sjögren’s syndrome (pSS) is a common systemic autoimmune disease characterized by chronic inflammation and dysfunction of the salivary and lacrimal glands [1, 2]. In this disease, the patient faces many personal and social issues. Therefore, it can affect the mental health of the patient and the social health of the society. For this reason, despite the high costs incurred for the diagnosis and treatment of the disease, it can cause a decrease in the quality of life and depression in patients [3]. In pSS, extra glandular organ systems such as lungs, kidneys, small vessels, and other endocrine glands are also implicated [4]. Sjögren’s syndrome is associated with many diseases, including an increased risk of non-Hodgkin’s lymphoma[5]. But regarding extra glandular manifestations, pulmonary complications rank at the top as having a higher prevalence in pSS compared to secondary type [6, 7], ranging from 9-75% according to the diagnostic method used, including small airway disease, parenchymal alteration, and interstitial involvement [8].

Among the pulmonary manifestations of pSS, interstitial lung disease (ILD) is by far the most common [9-11], with prevalences ranging between 8% and 39.1%. ILD causes airway obstruction in patients [12, 13]. Various factors contribute to the development of ILD [14]. Differences in prevalence can be due to various factors, including diagnostic criteria, environmental factors, race, the presence of underlying disease, and other factors [15-17]. The most frequently encountered subtype of interstitial lung disease is non-specific interstitial pneumonia (NSIP), whereas other sorts are usual interstitial pneumonia (UIP), lymphocytic interstitial pneumonia (LIP), and organizing pneumonia (OP) [18-21]. Interstitial lung disease is a common extraglandular complication related to survival in patients with pSS, which lowers the quality of life of those affected and serves as one of the frequent causes of premature death [22-25]. Conversely, systemic autoimmune diseases have been postulated to increase the risk of interstitial lung disease as reported in previous studies [26]. The prevalence of ILD in pSS patients has been reported differently and has been studied in different populations with heterogeneous factors. Therefore, systematic reviews and meta-analyses can provide more accurate and reliable evidence on this issue. Given that limited studies have been conducted in this area, and systematic reviews can evaluate all factors affecting the frequency of ILD, we investigated this issue in this study.

Materials and Methods

Study Protocol

This study was designed to evaluate the prevalence of ILD in patients with pSS. The PRISMA protocol [27], which is specific for systematic review and meta-analysis studies, was used and registered on the PROSPERO website (CRD42024566698).

PICO Components

Population: Studies investigating the frequency or prevalence of ILD in patients with pSS were evaluated. Intervention: Not applicable. Comparison: Not applicable. Outcomes: The primary outcome was the prevalence of ILD in patients with pSS. Secondary outcomes included the prevalence of NSIP, UIP, LIP, and OP in patients with pSS.

Search Strategy

To access resources, international databases ProQuest, PubMed, Web of Science, Cochrane, Embase, and the search engine Google Scholar were searched until July 1, 2024, without any time and place restrictions, using keywords (Primary Sjogren’s Syndrome, Primary Sicca Syndrome, Prevalence, “Lung Diseases, Interstitial”, Interstitial Lung Disease, Interstitial Pneumonia) and their MeSH equivalents. Keywords were combined with operators (AND, OR), and an advanced search was performed. The list of resources of selected studies in the electronic search phase was manually reviewed. The search strategy in the PubMed database is mentioned in this section: ((Primary Sjogren's Syndrome OR Primary Sicca Syndrome) AND ("Lung Diseases, Interstitial" OR Interstitial Lung Disease OR Interstitial Pneumonia)) AND (Prevalence)

Inclusion and Exclusion Criteria

Studies that had investigated the prevalence of ILD in patients with pSS were included in the meta-analysis. The following studies were excluded from the meta-analysis: studies where the type of Sjögren’s disease was not specified - letters to the editor - case reports - duplicate studies - studies where their data were incomplete - review studies - studies that did not have full text - studies with poor quality.

Qualitative Assessment

Two authors evaluated the studies with the Newcastle Ottawa Scale checklist. In this checklist, a star system was used, such that a maximum of one star was given for each question, and only the question related to comparison had the possibility of allocating two stars. Therefore, the lowest score on the checklist was zero (lowest quality), and the highest score was ten (highest quality). The cut-off point in this study was considered six [28].

Data Extraction

Two authors independently performed data extraction, and disagreements were resolved by a third researcher. From each study, information such as author’s name, type of study, sample size, country, number of women and men, year, average age, prevalence of ILD in patients with pSS in all individuals, prevalence of ILD in women with pSS, prevalence of ILD in men with pSS, prevalence of ILD subgroups in patients with pSS was extracted.

Statistical Analysis

Metaprop implements procedures which are specific to binomial data and allows computation of exact binomial and score test-based confidence intervals. It provides appropriate methods for dealing with proportions close to or at the margins where the normal approximation procedures often break down, by use of the binomial distribution to model the within-study variability or by allowing Freeman-Tukey double arcsine transformation to stabilize the variances. Sensitivity analysis was also used to determine the most influential studies resulting from the current meta-analysis. Subgroup analysis and meta-regression were used to investigate the sources of heterogeneity, and the Funnel plot was used to assess publication bias. The I2 index has three classifications (<25% indicates low heterogeneity, between 25% and 75% shows moderate heterogeneity and >75% indicates high heterogeneity). Due to the moderate heterogeneity, this study applied a random-effects model. Data analysis was performed with STATA 14 software (developed by Computing Resource Center in California) , and the significance level of the tests was considered P<0.05.

Results

Study Selection

There was a total of 302 studies at the initial stage. The study titles were screened, and 142 duplicate studies were removed. Abstracts of studies were assessed, and we excluded 14 studies because they did not have full text. The full text of the remaining 61 articles was evaluated; then41 studies without essential data were excluded. Seven further studies were excluded based on other items from the exclusion criteria, and 34 articles entered the systematic review and meta-analysis (Figure-1). This meta-analysis included 34 observational studies involving a population sample of 9535 individuals. Of these 34 studies, 26 were cohort studies, 5 were case-control studies, and 3 were cross-sectional studies. The studies were published from 1985 to 2024 (Table-1).

When excluding the studies of Sahin Ozdemirel [40] and Kvarnstrom [54], which were considered outliers, the overall prevalence estimate for ILD in pSS patients was 23.5% (95%CI: 18.6%, 28.4%) (Figure-2A). Furthermore, the prevalence of ILD in women with pSS was 31.2% (95%CI: 18.4%, 44.1%), and in men was 45.5% (95%CI: 23.6%, 67.4%) (Figures-2B and -2C). Consequently, the incidence of ILD in male patients with pSS was higher than in female patients, and the male gender could be considered an independent risk factor for developing ILD. As shown in Figure-2D, the subgroup analysis according to age detected a prevalence of ILD in patients with pSS:

• Age 30-39 years: 22.2% (95%CI: 18.9%, 26%)

• Age 40-49 years: 10.8% (95%CI: 8.7%, 12.9%)

• Age 50-59 years: 27.6% (95%CI: 17.9%, 37.4%)

• Age 60-69 years: 23.3% (95%CI: 17.9%, 28.7%)

Age was not statistically significantly associated with pSS-associated ILD, and the highest prevalence of ILD was in the age group of 50 to 59 years.

Regarding study design, the prevalence of ILD among pSS patients in:

• Case-control studies was 15.6% (95%CI: 7.1%, 24.1%)

• Cohort studies was 25.7% (95%CI: 19%, 32.4%)

• Cross-sectional studies was 21.4% (95%CI: 11.9%, 31%) (Figure-2E)

In patients with pSS, the prevalence of NSIP was 48.8% (95%CI: 41.4%, 56.2%), the prevalence of UIP was 15% (95%CI: 10.5%, 19.5%), the prevalence of LIP was 10.8% (95%CI: 6.6%, 15%), and the prevalence of OP was 9.4% (95%CI: 5.4%, 13.4%). Therefore, the most common type of ILD in patients with pSS, in order, was NSIP, UIP, OP, and LIP (Figures-3A-D). Figure-4 shows a meta-regression, indicating there was no statistically significant relationship between the prevalence of ILD in patients with pSS and the sample size of the studies (P=0.608). Moreover, Figure-5 demonstrates that the relationship between the prevalence of ILD in patients with pSS and the year of publication of the studies was not statistically significant (P=0.841). The publication bias diagram was significant (P=<0.001) and showed that studies that reported a high prevalence of ILD in patients with primary Sjögren's syndrome had a lower chance of publication (Figure-6). Sensitivity analysis showed that the studies by Wang Y (2018) and Kvarnstrom M (2015) were the most influential studies in the current research results (Figure-7).

Discussion

In this meta-analysis, 34 observational studies were combined, and a total of 9535 patients with pSS were examined. The results revealed that the prevalence of ILD in all patients with pSS was 23.5%, and in women and men, it was 31.2% and 45.5%, respectively. Moreover, the prevalence of ILD in patients aged 30 to 39 years was 22.2%, 40 to 49 years was 10.8%, 50 to 59 years was 27.6%, and 60 to 69 years was 23.3%. In terms of types of ILD, the prevalence of NSIP in patients was 48.8%, UIP was 15%, LIP was 10.8%, and OP was 9.4%. In the current meta-analysis, NSIP was the most common type of ILD. In another study, the authors estimated a combined prevalence of 52% for NSIP and 44% for UIP in patients with pSS [60], which is consistent with the results of our study.

In 2024, in a cohort study conducted by Manikuppam and colleagues, which included 550 patients with pSS with an average age of 50 years, the prevalence of ILD was estimated to be 6%. This study was retrospective and the average age of the patients was close to 50 years. On the other hand, all patients were evaluated from one center. Therefore, these factors could be influential in the discrepancy between the results and the results of the present study [29].

In a study conducted by Lin and colleagues in 2022 on 333 patients with pSS, a retrospective study showed that the prevalence of ILD was 19.82%. In this study, it was found that the prevalence of ILD was higher in Asian populations than in Europeans. In contrast, in the present study, Iranian races were evaluated [35]. In another cohort study conducted by Guo and colleagues in 2021 on a large Chinese group consisting of 563 patients with pSS and 172 patients with secondary Sjögren’s syndrome, the prevalence of ILD in patients with pSS was 42.6% [38]. In a case-control study conducted by Gao and colleagues in 2018 on 853 patients with pSS, the aim of which was to investigate the prevalence, risk factors, and prognosis of ILD in patients with pSS, ILD was observed in 165 patients (19.34%) [19]. In another study conducted by Huang and colleagues in 2023 using a case-control method, the analysis of 274 patients with pSS showed that the prevalence of ILD was 22.3% [32]. Furthermore, due to the wide range of prevalence of ILD in patients with pSS, a systematic review and meta-analysis was required to perform. In some studies, the prevalence of ILD in patients with pSS was low, but on the other hand, in some studies, we faced a high prevalence of ILD in patients with pSS.

The difference in the prevalence of ILD in different studies compared to the present study could be influenced by various factors. These factors include geographical regions, race, age of patients, type of study, diagnostic criteria, and other factors. Therefore, factors can influence the frequency of ILD in different studies.

In a meta-analysis conducted in 2022 by Arbiv and colleagues to investigating the prevalence and radiological patterns of ILD in Sjögren’s syndrome, the prevalence of ILD was about 15% [61]. In the current meta-analysis, in line with the previous study, the prevalence of ILD in patients with pSS was 25. Although in the current study, only patients with pSS were examined, while in the previous study, patients with primary and secondary Sjögren’s were examined together.

In a systematic review conducted in 2020 by Sambataro and colleagues, the results showed that about 20% of pSS patients have ILD [62]. In a meta-analysis conducted by He and colleagues in 2020, in 23 studies with 6157 patients, the prevalence of ILD in patients with pSS was 13% [18]. Another meta-analysis by Joy and colleagues in 2023 aimed to investigate the prevalence, imaging patterns, and risk factors of ILD in connective tissue disease, and the prevalence of ILD in patients with pSS was 17% [63]. In 2023, in a meta-analysis conducted by Berardicurti and colleagues to investigate the prevalence of ILD in pSS, the combined prevalence of pSS-ILD was 23% [60]. In the current meta-analysis, which is the most up-to-date meta-analysis conducted in this field, the prevalence of ILD in patients with pSS has increased compared to previous meta-analyses, and considering the impact that ILD has on the quality of life and mortality of patients, this issue is very concerning.

Strengths of the current study include: )1) In the previous meta-analysis (Berardicurti), the databases PubMed, Embase, and Cochrane were searched until December 2022. While in the current meta-analysis, the databases ProQuest, PubMed, Web of Science, Cochrane, and Embase were searched until July 2024. )2) The number of studies and sample size in the current meta-analysis were greater than the number of studies and sample size in the previous meta-analysis (Berardicurti). )3) the prevalence of ILD in patients with pSS was presented by age and gender of patients, which was not present in the previous meta-analysis (Berardicurti). )4) the prevalence of NSIP and UIP, which were presented in the previous meta-analysis, the prevalence of LIP and OP was also reported in patients with pSS. )5) the results of the prevalence estimate of ILD in patients with pSS were reported by type of studies to reduce heterogeneity.

Conclusion

One in four patients with pSS has ILD. Since ILD has degrees and is in mild and asymptomatic stages, its identification is not easy, even this prevalence may be higher. On the other hand, the prevalence of ILD was higher in men than in women. For this reason, men with pSS are more at risk of ILD than women. Also, the prevalence of ILD in the age group of 50 to 59 years was higher than other groups. In addition, the most common type of ILD is NSIP, and almost one in two people is affected by NSIP. As you can see, the statistics are very high and worrying. Therefore, it is recommended that patients with pSS, especially men and people who are 50 to 59 years old, be screened for ILD, as they are considered a high-risk group.

Conflict of Interest

The authors declare that they have no conflict of interest.

Prevalence of Interstitial Lung Disease in Patients with Primary Sjogren’s Syndrome

Molahoseini M, et al.

GMJ.2025;14:e3752 www.gmj.ir

3

Molahoseini M, et al.

Prevalence of Interstitial Lung Disease in Patients with Primary Sjogren’s Syndrome

4	GMJ.2025;14:e3752 www.gmj.ir

Prevalence of Interstitial Lung Disease in Patients with Primary Sjogren’s Syndrome

Molahoseini M, et al.

GMJ.2025;14:e3752 www.gmj.ir

5

Table 1. Characteristics of Articles

Author, Year	Location	Design	Sample size	Age group (year)	Number of female	Number of male	Duration of study	Prevalence of ILD in patients with pSS (%)	Prevalence of ILD in female (%)	Prevalence of ILD in male (%)	Score of Newcastle Ottawa Scale
Manikuppam P, 2024[29]	India	Cohort	550	50	NR	NR	From 2010 to 2019	6	NR	NR	9
Yang Z, 2024[30]	China	Cohort	256	63.36	240	16	From October 2017 to January 2022	39.8	40.8	25	8
Wang Y, 2024[31]	China	Case-control	622	NR	NR	NR	NR	18.8	NR	NR	8
Huang Y, 2023[32]	China	Case-control	274	NR	NR	NR	From August 2013 to August 2022	22.3	NR	NR	9
Lee KA, 2023[33]	Korea	Cohort	120	60.35	107	13	Between 2013 and 2021	32.5	29.9	53.8	8
He SH, 2022[34]	China	Cohort	83	NR	NR	NR	NR	18.9	NR	NR	7
Lin W, 2022[35]	China	Cohort	333	54	310	23	From September 2016 to March 2019	19.8	18.7	34.7	8
Isik OO, 2022[36]	Turkey	Cross-sectional	120	55.9	NR	NR	Between 2004 and 2019	13.3	NR	NR	7
Weng L, 2022[37]	China	Cohort	69	55.04	NR	NR	Between September 2013 and June 2017	28	NR	NR	7
Guo T, 2021[38]	China	Cohort	563	53	508	55	From January 2010 to May 2020	42.6	40.9	58.2	9
Continued on the next page

Molahoseini M, et al.

Prevalence of Interstitial Lung Disease in Patients with Primary Sjogren’s Syndrome

6	GMJ.2025;14:e3752 www.gmj.ir

Prevalence of Interstitial Lung Disease in Patients with Primary Sjogren’s Syndrome

Molahoseini M, et al.

GMJ.2025;14:e3752 www.gmj.ir

7

Molahoseini M, et al.

Prevalence of Interstitial Lung Disease in Patients with Primary Sjogren’s Syndrome

8	GMJ.2025;14:e3752 www.gmj.ir

Prevalence of Interstitial Lung Disease in Patients with Primary Sjogren’s Syndrome

Molahoseini M, et al.

GMJ.2025;14:e3752 www.gmj.ir

9

Molahoseini M, et al.

Prevalence of Interstitial Lung Disease in Patients with Primary Sjogren’s Syndrome

10	GMJ.2025;14:e3752 www.gmj.ir

Prevalence of Interstitial Lung Disease in Patients with Primary Sjogren’s Syndrome

Molahoseini M, et al.

GMJ.2025;14:e3752 www.gmj.ir

11

Molahoseini M, et al.

Prevalence of Interstitial Lung Disease in Patients with Primary Sjogren’s Syndrome

12	GMJ.2025;14:e3752 www.gmj.ir

Prevalence of Interstitial Lung Disease in Patients with Primary Sjogren’s Syndrome

Molahoseini M, et al.

GMJ.2025;14:e3752 www.gmj.ir

13

Molahoseini M, et al.

Prevalence of Interstitial Lung Disease in Patients with Primary Sjogren’s Syndrome

14	GMJ.2025;14:e3752 www.gmj.ir

References

1. Zhang N, Shi Q, Yao Q. Epidemiological studies on primary Sjogren's syndrome. Zhonghua Nei Ke Za Zhi. 1993 ; 32(8): 522-4.
2. Mariette X , Criswell L. Primary Sjögren’s syndrome. N Engl J Med. 2018 Mar; 378(10): 931-9.
3. Tarn J, et al. Primary Sjögren's syndrome: Longitudinal real-world, observational data on health-related quality of life. J Intern Med. 2022; 291(6): 849-855.
4. Tsuboi H, et al. Primary and secondary surveys on epidemiology of Sjögren's syndrome in Japan. Mod Rheumatol. 2014 May; 24(3): 464-70.
5. Ansari N, Salesi M. The association between primary Sjogren's syndrome and non-Hodgkin's lymphoma: a systematic review and meta-analysis of cohort studies. Clin Rheumatol. 2024; 43(7): 2177-2186.
6. Parambil J, et al. Interstitial lung disease in primary Sjögren syndrome. Chest. 2006; 130(5): 1489-95.
7. Fauchais A, et al. Immunological profile in primary Sjögren syndrome: clinical significance, prognosis and long-term evolution to other auto-immune disease. Autoimmun Rev. 2010 Jul; 9(9): 595-9.
8. Gardiner P, et al. Pleuropulmonary abnormalities in primary Sjögren's syndrome. J Rheumatol. 1993; 20(5): 831-7.
9. Palm Ø, et al. Clinical pulmonary involvement in primary Sjögren’s syndrome: prevalence, quality of life and mortality—a retrospective study based on registry data. Rheumatology (Oxford). 2013; 52(1): 173-9.
10. Luppi F, et al. Interstitial lung disease in Sjögren’s syndrome: a clinical review. Clin Exp Rheumatol. 2020 ; 38: 291-300.
11. HaghighiKian SM, et al. A holistic approach to implementing artificial intelligence in lung cancer. Indian J Surg Oncol. 2025 Feb;16(1):257-78.
12. Rezaeeyan H, Nobakht M Gh, Arabfard M. A computational approach for the identification of key genes and biological pathways of chronic lung diseases: a systems biology approach. BMC Med Genomics. 2023; 16(1): 159.
13. Rezaeeyan H, et al. Evaluation of common protein biomarkers involved in the pathogenesis of respiratory diseases with proteomic methods: A systematic review. Immun Inflamm Dis. 2023; 11(11): e1090.
14. Ahmadipour E, et al. Understanding kidney injury in COVID-19; a pressing priority. J Nephropharmacol. 2020; 10(2): e19-e19.
15. Dong X, et al. A retrospective analysis of distinguishing features of chest HRCT and clinical manifestation in primary Sjögren’s syndrome-related interstitial lung disease in a Chinese population. Clin Rheumatol. 2018 Nov; 37(11): 2981-8.
16. Roca F, et al. Interstitial lung disease in primary Sjögren's syndrome. Autoimmun Rev. 2017; 16(1): 48-54.
17. Manfredi A, et al. Prevalence and characterization of non-sicca onset primary Sjögren syndrome with interstitial lung involvement. Clin Rheumatol. 2017 Jun; 36(6): 1261-8.
18. He C, et al. Prevalence and risk factors of interstitial lung disease in patients with primary Sjögren's syndrome: a systematic review and meta-analysis. Int J Rheum Dis. 2020 Aug; 23(8): 1009-18.
19. Gao H, et al. Prevalence, risk factors, and prognosis of interstitial lung disease in a large cohort of Chinese primary Sjögren syndrome patients: a case-control study. Medicine. 2018; 97(24): e11003.
20. Kamiya Y, et al. Prognostic factors for primary Sjögren's syndrome-associated interstitial lung diseases. Respir Med. 2019 Nov; 159: 105811.
21. Moradi G, et al. Evaluating the Cavitary Lung Lesions on CT Scan of COVID-19 Patients: A Retrospective Study. J Community Hosp Intern Med Perspect. 2024; 14(6): 23.
22. Cottin V, et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018 Dec; 27(150): 180076.
23. Cottin V, et al. Fibrosing interstitial lung diseases: knowns and unknowns. Eur Respir Rev. 2019 Mar; 28(151): 180100.
24. Raji H, et al. Clinical, radiological outcomes and pulmonary function tests in patients recovered from COVID-19 in a three-month follow-up. Immunopathol Persa. 2024; 10(1): e31362.
25. Adereh A, et al. Loc646329 sponges miR-21 to reduce RAS/MAP kinase signaling pathway in oral squamous cell carcinoma (OSCC). Naunyn Schmiedebergs Arch Pharmacol. 2024; 398: 1-9.
26. Ng K, et al. Risk of interstitial lung disease in patients with newly diagnosed systemic autoimmune rheumatic disease: a nationwide, population-based cohort study. Semin Arthritis Rheum. 2020 Oct; 50(5): 840-845.
27. Moher D, et al. Preferred reporting items for systematic review and metaanalysis protocols (PRISMA-P) 2015 statement. Syst Rev J. 2015; 4: 1-9.
28. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25: 603-5.
29. Manikuppam P, et al. Clinical Characteristics and Outcomes of Interstitial Lung Disease in Primary Sjögren's Syndrome: A Retrospective Cohort Study. Mediterr J Rheumatol. 2024 Mar; 35(1): 108-114.
30. Yang Z, et al. Clinical features and risk factors for primary Sjögren’s syndrome combined with interstitial lung disease: a retrospective study. Acta Biochim Pol. 2024 Apr; 71: 12461.
31. Wang Y, et al. Predicting the risk of interstitial lung disease in patients with primary Sjögren's syndrome: Novel nomogram and elevated Th2 cells. Mol Immunol. 2024 Apr;168: 25-37.
32. Huang Y, et al. Risk factors and prognosis of interstitial lung disease for primary Sjögren syndrome patients: A retrospective case‒control study. Clin Rheumatol. 2023 Nov; 42(11): 3033-41.
33. Lee K, et al. Clinical course and risk factors for development and progression of interstitial lung disease in primary Sjögren’s syndrome. Sci Rep. 2023 Jun; 13(1): 9189.
34. He S, et al. Risk factors for progression of interstitial lung disease in Sjögren’s syndrome: a single-centered, retrospective study. Clin Rheumatol. 2022 Apr; 41(4): 1153-1161.
35. Lin W, et al. Interstitial lung disease in Primary Sjögren's syndrome . BMC Pulm Med. 2022 Feb; 22(1): 73.
36. Işik Ö, Yazici A, Çefle A. The respiratory manifestations in patients with primary Sjögren s syndrome: is interstitial lung disease related to disease activity? Turk J Med Sci. 2022; 52(5): 1704-1712.
37. Weng L, et al. Biomarkers of interstitial lung disease associated with primary Sjögren's syndrome. Eur J Med Res. 2022 Oct; 27(1): 199.
38. Guo T, et al. Clinical profiles of SS-ILD compared with SS-NILD in a Chinese population: a retrospective analysis of 735 patients. Ann Med. 2021 Jan; 53(1): 1340-8.
39. Zhang K, et al. The ratio of neutrophil to lymphocyte predicts interstitial lung disease and its prognosis in patients with primary Sjogren’s syndrome: a retrospective analysis. Ann Palliat Med. 2021 Jun; 10(6): 6493501-6501.
40. Sahin Ozdemirel T, et al. The evaluation of lung involvement and functional capacities in patients diagnosed with primary Sjogren’s syndrome. Int J Clin Pract. 2021 Oct; 75(10): e14635.
41. Yazisiz V, et al. Survival analysis of patients with Sjögren’s syndrome in Turkey: a tertiary hospital-based study. Clin Rheumatol. 2020 Jan; 39(1): 233-41.
42. Goules A, et al. Primary Sjögren’s syndrome of early and late onset: distinct clinical phenotypes and lymphoma development. Front Immunol. 2020 Oct; 11: 594096.
43. Zhao R, et al. Associated factors with interstitial lung disease and health-related quality of life in Chinese patients with primary Sjögren’s syndrome. Clin Rheumatol. 2020 Feb; 39(2): 483-9.
44. Heus A, et al. Pulmonary involvement in primary Sjögren’s syndrome, as measured by the ESSDAI. Scand J Rheumatol. 2020 Jan; 49(1): 38-46.
45. Sogkas G, et al. Lung Involvement in Primary Sjögren's Syndrome—An Under-Diagnosed Entity. Front Med (Lausanne). 2020 Jul; 7: 332.
46. Shi L, et al. Increases in tumor markers are associated with primary Sjögren’s syndrome-associated interstitial lung disease. Ther Adv Chronic Dis. 2020 Jul; 11: 1–9.
47. Guisado-Vasco P, et al. Quantitative assessment of interstitial lung disease in Sjögren’s syndrome. PLoS One. 2019 Nov; 14(11): e0224772.
48. Wang Y, et al. Risk factors for primary Sjögren syndrome-associated interstitial lung disease. J Thorac Dis. 2018 Apr; 10(4): 2108-2117.
49. Kakugawa T, et al. Lymphocytic focus score is positively related to airway and interstitial lung diseases in primary Sjögren's syndrome. Respir Med. 2018 Apr; 137: 95-102.
50. Kampolis C, et al. Prevalence and spectrum of symptomatic pulmonary involvement in primary Sjögren’s syndrome. Clin Exp Rheumatol. 2018 ;36(Suppl 112): 94-101.
51. Ramírez Sepúlveda J, et al. Long-term follow-up in primary Sjögren’s syndrome reveals differences in clinical presentation between female and male patients. Biol Sex Differ. 2017; 8(1): 25.
52. Ter Borg E, Kelder j. Development of new extra-glandular manifestations or associated auto-immune diseases after establishing the diagnosis of primary Sjögren’s syndrome: A long-term study of the Antonius Nieuwegein Sjögren (ANS) cohort. Rheumatol Int. 2017 Jul; 37(7): 1153-1158.
53. Li X, et al. Clinical and laboratory profiles of primary Sjogren's syndrome in a Chinese population: A retrospective analysis of 315 patients. Int J Rheum Dis. 2015; 18(4): 439-46.
54. Kvarnström M, et al. Incident cases of primary Sjögren’s syndrome during a 5-year period in Stockholm County: a descriptive study of the patients and their characteristics. Scand J Rheumatol. 2015 Mar; 44(2): 135-42.
55. Ter Borg E , Kelder j. Lower prevalence of extra-glandular manifestations and anti-SSB antibodies in patients with primary Sjögren’s syndrome and widespread pain: evidence for a relatively benign subset. Clin Exp Rheumatol. 2014 May; 32(3): 349-53.
56. Nannini C, et al. Primary Sjögren's syndrome 1976–2005 and associated interstitial lung disease: a population-based study of incidence and mortality. BMJ Open. 2013 Nov; 3(11): e003569.
57. Lin D, et al. Clinical and prognostic characteristics of 573 cases of primary Sjögren's syndrome. Chin Med J (Engl). 2010; 123(22): 3252-7.
58. Papathanasiou M, et al. Reappraisal of respiratory abnormalities in primary and secondary Sjogren's syndrome: a controlled study. Chest. 1986 ; 90(3): 370-4.
59. Constantopoulos S, Papadimitriou C, Moutsopoulos H. Respiratory manifestations in primary Sjögren's syndrome: a clinical, functional, and histologic study. Chest. 1985 Aug; 88(2): 226-9.
60. Berardicurti O, et al. Interstitial lung disease and pulmonary damage in primary sjögren’s syndrome: a systematic review and meta-analysis. J Clin Med. 2023 Mar; 12(7): 2586.
61. Arbiv O, et al. Prevalence and Radiologic Patterns of Interstitial Lung Disease in Sjogren Syndrome: A Systematic Review and Meta-Analysis. Am J Respir Crit Care Med. 2022; 205: A2743.
62. Sambataro G, et al. Clinical, morphological features and prognostic factors associated with interstitial lung disease in primary Sjӧgren's syndrome: a systematic review from the Italian Society of Rheumatology. Autoimmun Rev. 2020 Feb; 19(2): 102447.
63. Joy G, et al. Prevalence, imaging patterns and risk factors of interstitial lung disease in connective tissue disease: a systematic review and meta-analysis. Eur Respir Rev. 2023 Mar; 32(167): 220210.

Prevalence of Interstitial Lung Disease in Patients with Primary Sjogren’s Syndrome

Molahoseini M, et al.

GMJ.2025;14:e3752 www.gmj.ir

15

Molahoseini M, et al.

Prevalence of Interstitial Lung Disease in Patients with Primary Sjogren’s Syndrome

16	GMJ.2025;14:e3752 www.gmj.ir